Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)

This study will investigate if modulating the tumor microenvironment with biologic agents like XL-092 will have synergistic effect when combined with checkpoint based immunotherapeutic treatment of patients with hepatocellular carcinoma (HCC).

Trial Details

NCT ID
NCT06698250
Phase
PHASE2
Sponsor
Anwaar Saeed
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Zanzalintinib
  • Durvalumab
  • Tremelimumab
Locations (sample)
  • Pittsburgh, Pennsylvania, United States|40.44062,-79.99589
  • Houston, Texas, United States|29.76328,-95.36327
  • San Antonio, Texas, United States|29.42412,-98.49363

Key Eligibility Criteria

  • Patients must have unresectable hepatocellular carcinoma.
  • Patients must be treatment naïve for systemic therapy in the unresectable setting.
  • ≥ 18 years and ECOG performance status 0-1
  • Recovery to baseline or ≤ Grade 1 severity (CTCAE v5) from adverse events (AEs), unless AE(s) are clinically nonsignificant and/or stable on support…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →